Home›Trial›NCT07214727
NCT07214727Phase 1RECRUITING

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Study Summary

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

Conditions
Alzheimer's Disease
Interventions / Drugs
ALN-5288Placebo
View on ClinicalTrials.gov ↗
Sponsor
ALNY
Alnylam Pharmaceuticals
RNAi Therapeutics
F27/100
Study Details
Enrollment50 participants
Primary Completion—
Lead SponsorAlnylam Pharmaceuticals
Data Retrieved2026-04-11 02:53:26.219297+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 50 participants
Sponsor Catalyst Profile

Alnylam Pharmaceuticals (ALNY) is the sponsoring company for this trial. BiotechSign currently grades this company F (27/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ALNY Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.